Leerink on Fulcrum Therapeutics (FULC): 'We believe this is a positive sign for FULC'
Tweet Send to a Friend
Leerink Partners analyst Joseph P. Schwartz reiterated an Outperform rating and $47.00 price target on Fulcrum Therapeutics (NASDAQ: FULC).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
